Ashfield Capital Partners’s iShares Biotechnology ETF IBB Stock Holding History

Ashfield Capital Partners’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$3.83M	Sell	32,703 -2,650	-7%	-$329K	0.32%	70
2022 Q2	$4.16M	Sell	35,353 -515	-1%	-$61.1K	0.32%	68
2022 Q1	$4.67M	Sell	35,868 -510	-1%	-$66.4K	0.3%	73
2021 Q4	$5.55M	Sell	36,378 -2,075	-5%	-$321K	0.36%	67
2021 Q3	$6.22M	Sell	38,453 -9	-0%	-$1.51K	0.44%	59
2021 Q2	$6.29M	Sell	38,462 -94	-0.2%	-$14.5K	0.45%	57
2021 Q1	$5.8M	Buy	38,556 +80	+0.2%	+$12.7K	0.46%	60
2020 Q4	$5.83M	Buy	38,476 +508	+1%	+$72.6K	0.47%	57
2020 Q3	$5.14M	Sell	37,968 -127	-0.3%	-$17.2K	0.47%	59
2020 Q2	$5.21M	Sell	38,095 -1,997	-5%	-$255K	0.51%	54
2020 Q1	$4.32M	Buy	40,092 +592	+1%	+$68.2K	0.53%	50
2019 Q4	$4.76M	Sell	39,500 -4,404	-10%	-$491K	0.47%	57
2019 Q3	$4.37M	Buy	+43,904	New	+$4.6M	0.47%	58
2019 Q2	–	Sell	-45,075	Closed	-$4.79M	–	51
2019 Q1	$5.04M	Buy	45,075 +860	+2%	+$94.3K	0.55%	50
2018 Q4	$4.26M	Buy	44,215 +6,261	+16%	+$665K	0.56%	49
2018 Q3	$4.63M	Sell	37,954 -3,271	-8%	-$385K	0.52%	52
2018 Q2	$4.53M	Sell	41,225 -4,253	-9%	-$455K	0.57%	50
2018 Q1	$4.85M	Buy	45,478 +3,599	+9%	+$399K	0.63%	46
2017 Q4	$4.47M	Buy	41,879 +1,451	+4%	+$155K	0.58%	55
2017 Q3	$4.5M	Sell	40,428 -393	-1%	-$42K	0.6%	52
2017 Q2	$4.22M	Buy	40,821 +3,858	+10%	+$380K	0.58%	56
2017 Q1	$3.61M	Buy	36,963 +348	+1%	+$33.3K	0.5%	64
2016 Q4	$3.24M	Sell	36,615 -4,089	-10%	-$372K	0.32%	80
2016 Q3	$3.93M	Buy	40,704 +411	+1%	+$39.1K	0.32%	77
2016 Q2	$3.46M	Buy	40,293 +1,326	+3%	+$119K	0.28%	76
2016 Q1	$3.39M	Buy	38,967 +16,020	+70%	+$1.43M	0.25%	89
2015 Q4	$2.59M	Buy	22,947 +57	+0.2%	+$6.19K	0.18%	97
2015 Q3	$2.31M	Sell	22,890 -18	-0.1%	-$2.16K	0.15%	101
2015 Q2	$2.82M	Hold	22,908	–	–	0.15%	100
2015 Q1	$2.62M	Sell	22,908 -84	-0.4%	-$9.27K	0.14%	101
2014 Q4	$2.33M	Hold	22,992	–	–	0.11%	105
2014 Q3	$2.1M	Buy	22,992 +51	+0.2%	+$4.48K	0.1%	114
2014 Q2	$1.97M	Buy	22,941 +3	+0%	+$236	0.09%	119
2014 Q1	$1.81M	Buy	22,938 +513	+2%	+$42.7K	0.09%	117
2013 Q4	$1.7M	Buy	22,425 +2,325	+12%	+$165K	0.08%	119
2013 Q3	$1.4M	Sell	20,100 -120	-0.6%	-$7.86K	0.07%	124
2013 Q2	$1.17M	Buy	+20,220	New	+$1.17M	0.06%	133

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Ashfield Capital Partners's IBB Position: Q3 2022 in Review

Ashfield Capital Partners reduced its iShares Biotechnology ETF (IBB) stake by 7.5% in Q3 2022, selling an estimated $329K and leaving 32,703 shares worth $3.83M. The position accounts for 0.32% of the portfolio, ranked #70.

Ashfield Capital Partners first reported a position in IBB in Q2 2013 and has held it in 37 quarters since. The position peaked at $6.29M in Q2 2021. 829 funds tracked by Wall St. Rank hold IBB as of Q3 2022.

Ashfield Capital Partners held 32,703 shares of iShares Biotechnology ETF worth $3.83M as of Q3 2022.
Ashfield Capital Partners sold 2,650 iShares Biotechnology ETF shares in Q3 2022, an estimated $329K.
iShares Biotechnology ETF made up 0.32% of Ashfield Capital Partners's portfolio in Q3 2022, its #70 holding.
Ashfield Capital Partners first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 37 quarters since.
Ashfield Capital Partners's iShares Biotechnology ETF position peaked at $6.29M in Q2 2021.
829 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2022.

Based on Ashfield Capital Partners's 13F filing for Q3 2022, filed 10 Nov 2022.